| 货号 | 1693/50 |
| 别名 | 1,3-Dihydro-4-methyl-5-[4-(methylth |
| 供应商 | Tocris |
| 生物活性 | Inhibitor of type III phosphodiesterase (PDE3). Increases intracellular cyclic AMP (cAMP) concentrations and enhances myocardial contractility. Also induces concentration-dependent vasodilation in vitro. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 纯度 | >99 % |
| 计算分子量 | 248.3 |
| 分子式 | C12H12N2O2S |
| 可溶性/溶解性 | Soluble to 100 mM in DMSO |
| CAS号 | 77671-31-9 |
| 参考文献 | Junget al (2005) Pharmacological effects of ATI22-107 [2-(2-{2-[2-chloro-4-(6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-acetylamino}-ethoxymethyl)-4-(2-chloro-phenyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester)], a novel dual pharmacophore, on myocyte calcium cycling and contractility. J.Pharmacol.Exp.Ther. 312 517. PMID: 15550574. Pacher and Stanek (1999) Ambulatory vasodilator therapy in heart failure: systematic review of the literature and personal observational experience. Eur.J.Heart Fail. 1 263. PMID: 10935673. Vroomet al (1996) Effect of phosphodiesterase inhibitors on human arteries in vitro. Br.J.Anaesth. 76 122. PMID: 8672353. |